Sun Pharma shares ended 10 per cent increased at Rs 774.
Shares of the nation’s main drug maker – Sun Pharma – surged as a lot as 11 per cent to hit recent 52-week excessive of Rs 780.10 on the BSE after the corporate returned to revenue in quarter ended June 2021. The Mumbai-based firm reported web revenue of Rs 1,444.1 crore in contrast with a lack of Rs 1,655.6 crore within the corresponding interval a yr in the past. Its income from operations superior 28 per cent to Rs 9,718.74 crore versus Rs 7,585.25 crore in the identical interval final yr.
Sun Pharma’s earnings earlier than curiosity, tax, depreciation and amortisation (EBITDA) or working revenue superior 59 per cent yearly to Rs 2,771.8 crore leading to working revenue margin of 28.7 per cent.
During the quarter, Sun Pharma repaid debt of about $185 million and during the last 5 quarters, the corporate has repaid debt of about $765 million, Sun Pharma stated in a press launch.
“We witnessed a strong Q1, driven by a combination of robust core business growth, low base and some sale of Covid products. We are enthused by the all-round growth across all our businesses compared to Q4 last year. Our India business continues to do well while our global specialty revenues have grown over Q4. We are happy with Ilumya’s performance which has grown both YoY and sequentially. We continue to focus on growing our overall business and simultaneously strengthening our global specialty portfolio. The recent in-licensing of Winlevi for US and Canada is a step forward in this direction,” Dilip Shanghvi, Managing Director of the corporate stated in an announcement.
Sun Pharma’s gross sales in US rose 35 per cent yearly to $380 million, accounting for 29 per cent of complete consolidated gross sales and its gross sales in India rose 39 per cent to Rs 3,308 crore, accounting for 34 per cent of complete gross sales, , Sun Pharma stated.
Its consolidated analysis and growth (R&D) funding in first quarter of present monetary yr was Rs 592.6 crore as towards Rs 420.6 crore within the June quarter final yr.
Sun Pharma shares ended 10 per cent increased at Rs 774, outperforming the Sensex which ended on a flat be aware.
